Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Exegenesis Bio Closes $10 Million Initial Funding from China Investors

publication date: Oct 21, 2019

Exegenesis Bio, a Philadelphia gene therapy company, raised over $10 million in initial funding from China investors, K2VC, Kaitai Capital and Lenovo Star. The company is developing affordable first-in-class and best-in-class gene therapies for high unmet needs, which it will market in China and globally. The company's executive team averages 15 years experience in cell and gene therapy in US companies. Zhenhua Wu, PhD, founder and CEO of Exegenesis, previously worked at several innovative biopharmas in the Philadelphia area and also at GSK and Merck. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China